Latest news with #clinicalstage
Yahoo
8 hours ago
- Business
- Yahoo
PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases
Former Teva North America CEO Sven Dethlefs, PhD, to lead Celea BOSTON, August 12, 2025--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced the launch of a new Founded Entity Celea Therapeutics ("Celea"). Celea's mission is to deliver therapies that transform the lives of people with serious respiratory diseases. Its lead program, deupirfenidone (LYT-100), is a Phase 3-ready therapeutic candidate that holds promise across multiple fibrotic and inflammatory lung conditions and is initially being advanced for the treatment of idiopathic pulmonary fibrosis (IPF), a rare, progressive, and fatal lung disease. Sven Dethlefs, PhD, has been appointed to lead Celea, bringing deep expertise and a clear vision to accelerate the program's advancement. The launch of Celea reflects PureTech's commitment to advancing differentiated programs through focused, capital-efficient structures with seasoned leadership. Dr. Dethlefs is a proven pharmaceutical executive with more than 25 years of experience in global commercialization, R&D strategy, business development, and operations. He has played a central role at PureTech, driving forward the deupirfenidone program for more than a year. Prior to joining PureTech, Dr. Dethlefs served as CEO of Teva North America, where he oversaw the company's $8 billion specialty branded and generic businesses across the U.S. and Canada. At Teva, he also held senior leadership roles as Global Head of Marketing and Portfolio, Head of Respiratory Medicines, and COO Operations. He played a key role in the successful launch of AUSTEDO®, Teva's blockbuster treatment for Tardive Dyskinesia and Huntington's Disease, which is a deuterated form of tetrabenazine. Prior to joining Teva, Dr. Dethlefs was a partner at McKinsey & Company. He holds a PhD in Biochemistry. Dr. Sven Dethlefs commented: "Bringing meaningful innovation to patients with serious diseases has been a consistent theme throughout my career, and I believe deupirfenidone has the potential to be a true turning point in the treatment of IPF. Our Phase 2b data demonstrated the potential for best-in-class efficacy with a favorable safety and tolerability profile—addressing two of the most critical limitations of current therapies. The strength of the clinical data, combined with the team and mission behind Celea, make this a uniquely compelling opportunity. I'm excited to lead the next phase of development as we work to deliver a new standard of care for people living with IPF and other debilitating lung conditions." PureTech completed a successful Phase 2b trial of deupirfenidone in December 2024. A meeting with the U.S. Food and Drug Administration to discuss these results and the proposed Phase 3 trial design is expected by the end of the third quarter of 2025. Consistent with its capital-efficient innovation model, PureTech is pursuing third-party funding for Celea to advance the program through Phase 3 and potential commercialization. Robert Lyne, PureTech's Interim Chief Executive Officer, added: "The launch of Celea is an important value driver for PureTech. Sven brings deep experience in respiratory medicine and a strong track record of commercial success, including having played a critical role in the growth of AUSTEDO®, a deuterated medicine developed using the same underlying chemistry approach as deupirfenidone. He is uniquely suited to lead Celea and advance this important program." About Deupirfenidone (LYT-100)Deupirfenidone (LYT-100) is in development as a potential new standard of care for the treatment of idiopathic pulmonary fibrosis (IPF). It is a deuterated form of pirfenidone, which – along with nintedanib – is one of the two FDA-approved treatments for IPF. Both approved therapies offer only modest efficacy in slowing lung function decline, largely due to tolerability challenges that limit the ability to achieve higher doses that could significantly improve patient outcomes. These limitations have contributed to low treatment uptake and poor adherence, with approximately 25% of people with IPF in the U.S. ever receiving either drug. Despite this, combined peak global sales exceed $5 billion, representing a significant market opportunity in IPF and other fibrotic lung diseases. 1 Deupirfenidone may overcome these limitations. In the global Phase 2b ELEVATE IPF trial, deupirfenidone demonstrated the potential to stabilize lung function decline over at least 26 weeks as a monotherapy while maintaining a favorable safety and tolerability profile. Initial data from an ongoing open-label extension study suggest that this effect may be sustained through at least 52 weeks. These findings support the potential for deupirfenidone to offer a meaningful advance for people living with this progressive and deadly disease. Beyond IPF, deupirfenidone may also address multiple underserved fibrotic conditions, including progressive fibrosing interstitial lung diseases. About Idiopathic Pulmonary Fibrosis (IPF)Idiopathic pulmonary fibrosis (IPF) is a rare, progressive, and fatal lung disease characterized by irreversible scarring of lung tissue that leads to a steady decline in lung function. Median survival following diagnosis is estimated to be two to five years, and currently there is no cure.2 About Celea TherapeuticsCelea Therapeutics is dedicated to delivering transformative treatments for people with serious respiratory diseases. The company's lead program, deupirfenidone (LYT-100), is a Phase 3-ready therapeutic candidate with the potential to set a new standard of care for idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases. Celea was founded by PureTech Health plc (Nasdaq: PRTC, LSE: PRTC), a biotherapeutics company dedicated to giving life to science. PureTech's innovative R&D model drives the creation of Founded Entities like Celea, enabling the advancement of highly promising medicines to patients in a capital-efficient manner. For more information, please visit and About PureTech HealthPureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep portfolio through its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this portfolio of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points. For more information, visit or connect with us on X (formerly Twitter) @puretechh. 1 Esbriet peak sales (2020) per Roche 2021 Financial Results & Ofev peak sales (2024) per Boehringer Ingelheim 2024 Financial Results. Ofev sales include those for all approved indications – IPF, PF-ILD, and systemic sclerosis-associated interstitial lung disease (SSc-ILD). 2 Fisher, M., Nathan, S. D., Hill, C., Marshall, J., Dejonckheere, F., Thuresson, P., & Maher, T. M. (2017). Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis. Journal of Managed Care & Specialty Pharmacy, 23(3-b Suppl), S17–S24. Cautionary Note Regarding Forward-Looking StatementsThis press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements that relate to continued development of and regulatory interactions related to deupirfenidone, the potential of deupirfenidone in IPF and other indications, our expectations around our therapeutic candidates and approach towards addressing major diseases, our plans to advance our programs and deliver on our milestones, our future plans, prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. View source version on Contacts PureTech Public Relationspublicrelations@ Investor RelationsIR@ UK/EU Media Ben Atwell, Rob Winder+44 (0) 20 3727 1000puretech@ US Media Justin Chen+1 609 578 7230justin@ Sign in to access your portfolio
Globe and Mail
21 hours ago
- Business
- Globe and Mail
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
SAN DIEGO , Aug. 11, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Corporation" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Friday, August 8, 2025. A total of 37.42% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting. On a vote by ballot, the eight nominees proposed by the Corporation were elected as Directors of Oncolytics to serve until the Corporation's next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favor of individual nominees as follows: Director For % Withheld % Patricia Andrews 10,498,328 88.83 % 1,320,714 11.17 % Deborah M. Brown 10,115,110 85.58 % 1,703,932 14.42 % Jared Kelly 10,830,605 91.64 % 988,437 8.36 % Angela Holtham 10,175,887 86.10 % 1,643,155 13.90 % James T. Parsons 10,172,958 86.07 % 1,646,084 13.93 % Wayne Pisano 10,148,894 85.87 % 1,670,148 14.13 % Jonathan Rigby 9,508,770 80.45 % 2,310,272 19.55 % Bernd R. Seizinger 10,269,441 86.89 % 1,549,601 13.11 % In addition to the election of all nominees listed as directors in the management information circular, dated June 18 , 2025, Oncolytics shareholders approved all other resolutions placed before the meeting. These included fixing the number of directors of the Corporation for the ensuing year at eight and appointing the auditors for the Corporation for the ensuing year. For more details on the matters covered at the annual meeting, please refer to the Corporation's management information circular available on SEDAR at Final voting results on all matters voted on at the annual meeting will also be filed on SEDAR. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer and early-phase studies in anal and colorectal cancer. It induces anti-cancer immune responses by converting immunologically "cold" tumors "hot" through the activation of innate and adaptive immune responses. The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic pancreatic and breast cancers, both of which have received Fast Track designation from the FDA, and other gastrointestinal tumors. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: or follow the Company on social media on LinkedIn and on X @ oncolytics. Company Contact Jon Patton Director of IR & Communication jpatton@ Investor Relations for Oncolytics Mike Moyer LifeSci Advisors +1-617-308-4306 mmoyer@ Media Contact for Oncolytics Owen Blaschak LifeSci Communications oblaschak@ Logo - SOURCE Oncolytics Biotech® Inc.
Yahoo
a day ago
- Business
- Yahoo
Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108
PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs) Extended half-life and local bioactivation support convenient once-daily dosing in ulcerative colitis (UC) and fibrostenotic Crohn's disease (FSCD) Colon tissue drug levels exceeded target thresholds 36 hours post-dose in completed Phase 1a MAD cohort Company advancing toward IND submission for Phase 2 study in H1 2026 Carlsbad, CA, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ('Palisade', 'Palisade Bio', or the 'Company'), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced compelling new data from its ongoing clinical program evaluating PALI-2108, a first-in-class, ileocolonic-targeted PDE4 inhibitor, including positive topline results from its Phase 1b open-label cohort in patients with moderate-to-severe UC and colon tissue pharmacokinetic (PK) data from the Phase 1a multiple ascending dose (MAD) cohort. 'These results represent a significant milestone for PALI-2108,' said JD Finley, Chief Executive Officer of Palisade Bio. 'The early clinical activity, targeted delivery, dose flexibility, the potential for once-daily oral dosing and its favorable safety profile positions PALI-2108 as a potentially best-in-class oral therapy for patients with UC.' Dr. Mitchell Jones, Chief Medical Officer added, 'What is most compelling about the Phase 1b data is the remarkable consistency across all layers of assessment. The clinical response rate of 100% was tightly aligned with robust histologic improvements and a marked reduction in tissue lymphocytes—reflecting immunologic resolution. These effects were mechanistically supported by increased tissue cAMP levels and decreased PDE4B expression, confirming potent local target engagement. Additionally, RNA sequencing demonstrated coordinated downregulation across our inflammatory biomarker panel, fibrotic markers, PDE4 effector genes, and our companion diagnostic biomarker score, reinforcing both the breadth of pharmacodynamic activity and the precision medicine potential of PALI-2108.' Phase 1b UC Cohort: 100% Clinical Response with Strong Biomarker and Histology Improvements The 7-day, open-label Phase 1b study enrolled five patients with moderate-to-severe UC, receiving titrated BID dosing of PALI-2108 (30 mg BID). Key highlights include: Achieved 100% (5/5) clinical response (≥30% or ≥3-point reduction in modified Mayo score with rectal bleeding subscore ≤1) Mean reduction of 62.8% in modified Mayo score (−4.0 point absolute change) One patient achieved clinical remission Fecal calprotectin decreased in 4/5 patients (mean 70%) Plasma hsCRP decreased by 15% Showed histologic improvement across multiple indices: Nancy Index: 58% Robarts Histopathology Index: 56% Geboes Score: 36% Mechanistically, colon tissue analyses confirmed PDE4 inhibition and immunomodulation: Tissue cAMP increased in 4/5 patients Tissue lymphocytes decreased by an average of 40% PDE4B expression decreased by an average of 51% RNAseq data confirmed downregulation of inflammatory, fibrotic, and CDx biomarkers from baseline to end-of-study Importantly, PALI-2108 was well tolerated, with >95% of treatment-emergent adverse events (TEAEs) rated mild and transient (e.g., headache, nausea), and no SAEs, SUSARs (suspected unexpected adverse reactions), or discontinuations. Phase 1a MAD Cohort: Colon Tissue Drug Concentrations Confirm Extended Exposure and Once-Daily Dosing In parallel, Palisade Bio completed a comprehensive Phase 1a study in 84 healthy volunteers across SAD, MAD, and food-effect cohorts. Key results include: The PDE4 inhibitor active metabolite (PALI-0008) remained detectable in colon tissue ≥36 hours post-dose, maintaining levels near or above IC90 Steady-state trough concentrations exceeded IC90 with minimal accumulation Half-life of PALI-0008 exceeded that of any known PDE4 inhibitor, supporting sustained local activity PK modeling supports a once-daily dose regimen of 30 mg for both UC and FSCD Food reduced systemic exposure (~42% ↓ Cmax, ~20% ↓ AUC) but improved tolerability No SAEs or dose-limiting toxicities reported; >95% of TEAEs were mild and self-limited Based on these findings, Palisade Bio plans to complete a Phase 1b study in patients with fibrostenotic Crohn's disease by the second half of 2025. The Company's previously completed Phase 1a and 1b studies in ulcerative colitis, along with the upcoming FSCD study, will form the foundation for submitting a Phase 2 Investigational New Drug (IND) application and clinical protocols to the U.S. Food and Drug Administration (FDA) in the first half of 2026. For more information about the Phase 1a/b clinical study, visit and reference identifier NCT06663605. About PALI-2108 PALI-2108 is an orally administered prodrug engineered to deliver PDE4 inhibition selectively to the distal ileum and colon. The compound leverages a microbiome-activated mechanism to achieve regional bioactivation, minimize systemic exposure, and optimize mucosal tissue concentration. This localized approach reduces class-associated side effects while preserving anti-inflammatory and anti-fibrotic activity—a unique and clinically validated therapeutic strategy. About Palisade Bio Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to Forward Looking Statements Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to: statements regarding the safety and tolerability, PK and drug release characteristics, potential clinical efficacy and dosing requirements of PALI-2108 based on the Company's preclinical studies and data from its Phase 1a/b clinical study; indications and anticipated benefits of PALI-2108, including the potential of PALI-2108 to be a first-in-class and best-in-class therapy; and the expected timing of the Company's planned Phase 2 clinical studies. These forward-looking statements are based on the Company's current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company's forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company's clinical trials; the Company's reliance on PALI-2108, and its early stage of clinical development; the risk that prior results, such as signals of safety, activity, dosing or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company's product candidates in clinical trials focused on the same or different indications; the Company's ability to secure additional financing to fund future operations and development of its product candidates; and other factors that are described in the 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' sections of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on March 24, 2025, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Investor Relations Contact JTC Team, LLCJenene Thomas908-824-0775PALI@
Yahoo
4 days ago
- Business
- Yahoo
1 Reason to Buy MindMed (MNMD)
Key Points The company must operate under strict regulations, as it is developing certain medicines based on psychedelic substances. Such compounds are currently illegal for sale or consumption throughout much of America. These 10 stocks could mint the next wave of millionaires › By their nature, clinical-stage biotech companies can be volatile investments. Even by that standard, MindMed (NASDAQ: MNMD) is quite a risky play; after all, a key element of its business strategy is to develop brain health medications based on compounds that are illegal on the federal level in the U.S. Threading the needle with the law For this reason, even a modest relaxation of current laws could really benefit MindMed. It isn't cheap or easy to operate within the many restrictions imposed due to the legal status of psychedelics (these can be used for medical research purposes, however the limits are strict). That's exacerbated by the fact that the company's pre-revenue just now. So all things being equal, the more it can put the brakes on cash burn, the longer it'll survive until it can (hopefully) get one of its investigational drugs approved and shipped to the market. At the moment, MindMed has sufficient resources to endure for at least a few years. At the end of March it had nearly $238 million in cash, cash equivalents, and short-term investments, which wasn't too much less than the previous quarter's $245 million. According to management, this plus monies for the expected achievement of certain milestones will be sufficient to fund operations into 2028 at least. Thaw in progress Happily, the decriminalization of psychedelics, for medical purposes anyway, enjoys plenty of support among the American public. A 2023 survey conducted by the University of California at Berkeley found that 61% of respondents approved of regulated therapeutic access to psychedelic-based medicines. Meanwhile, in recent years certain jurisdictions relaxed their restrictions on psychedelics. Several cities, such as Denver and Washington D.C., have decriminalized psilocybin (the psychoactive compound in "magic" mushrooms). I don't think full-blown decriminalization is around the corner in the United States. Rather, I think it'll be more an unhurried, stop-and-go process like that of marijuana law reform currently. As restrictions on its research ease, MindMed should be able to save some capital and extend its all-important runway. Don't miss this second chance at a potentially lucrative opportunity Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $462,306!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $38,522!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $619,036!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. 1 Reason to Buy MindMed (MNMD) was originally published by The Motley Fool
National Post
5 days ago
- Business
- National Post
Devonian Announces Closing of a Private Placement of Units
Article content QUEBEC CITY — Devonian Health Group Inc. (' Devonian ' or the ' Corporation ') (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, announces that it has closed its non-brokered private placement for aggregate gross proceeds of $2,272,999.85 (the ' Offering '). The Offering consisted of the issuance of 15,153,332 units of the Corporation (the ' Units ') at a price of $0.15 per Unit. Each Unit consists of one subordinate voting share of the Corporation (a ' Share ') and one Share purchase warrant (a ' Warrant '). Each Warrant entitles the holder thereof to purchase one Share at an exercise price of $0.20 per Share for a period of 24 months from the date of issuance thereof. Article content Article content The proceeds of the Offering will primarily be used to finance working capital related to the Corporation's corporate overhead and research and development activities. Article content A total of $2,700.00 cash finder's fees were paid in connection with this Offering. The Shares and the Warrants issued pursuant to this Offering are subject to a restricted hold period of four months and one day, ending on December 8, 2025, under applicable Canadian securities laws. The Offering remains subject to the final approval of the TSX Venture Exchange. Article content About Devonian Article content Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian's focus is further supported by a U.S. Food and Drug Administration set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Article content Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare Inc., focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies. Article content Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability 'from the seed to the pill'. Devonian is traded publicly on the TSX Venture Exchange (the ' Exchange ') (TSXV: GSD) and on OTCQB exchange (OTCQB: DVHGF). Article content For more information, visit Cautionary Note Regarding Forward-Looking Statements All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating to the intended use of proceeds, the final approval of the TSX Venture Exchange in connection with the Offering and generally, the above 'About Devonian' paragraph, which essentially describes the Corporation's outlook, constitute 'forward-looking information' or 'forward-looking statements' within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release. Article content Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Corporation as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Article content By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. Article content This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended (the 'U.S. Securities Act') and may not be offered or sold to, or for the account or benefit of, persons in the United States or U.S. persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. 'United States' and 'U.S. person' are as defined in Regulation S under the U.S. Securities Act. Article content Article content Article content Article content Article content Contacts Article content
